San Francisco, Calif. -- King Pharmaceuticals announces the discontinuation of Procanbid (Procanamide Hydrochloride Extended-Release Tablets). The company says the drug is being discontinued because of understanding about current therapy and due to the availability of alternative anti-arrhythmics.
Procanbid tablets are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia.
To view a letter from the company, please visit: http://www.fda.gov/cder/drug/shortages/procanletter.pdf
Contact: Suvarna Bhatt at sbhatt@biospace.com.
